Share This Page
Drug Price Trends for NDC 00591-5661
✉ Email this page to a colleague
Average Pharmacy Cost for 00591-5661
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SULINDAC 150 MG TABLET | 00591-5661-05 | 0.18016 | EACH | 2025-11-19 |
| SULINDAC 150 MG TABLET | 00591-5661-01 | 0.18016 | EACH | 2025-11-19 |
| SULINDAC 150 MG TABLET | 00591-5661-05 | 0.17842 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00591-5661
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00591-5661
Introduction
The pharmaceutical landscape surrounding NDC (National Drug Code) 00591-5661 warrants a comprehensive evaluation given its market positioning, competitive dynamics, pricing trends, and future projections. This analysis synthesizes current market data, historical pricing trends, regulatory influences, and potential growth drivers to inform strategic decision-making for stakeholders ranging from investors to healthcare providers.
Product Overview
NDC 00591-5661 corresponds to Liraglutide (Victoza), a GLP-1 receptor agonist approved by the FDA for managing type 2 diabetes mellitus and obesity. Victoza’s expanding indication spectrum and established clinical profile contribute to its significant market presence. As of 2023, the drug remains a cornerstone in chronic disease management, with ongoing research expanding its therapeutic scope.
Market Landscape
Global and U.S. Market Size
The global GLP-1 receptor agonist market was valued at approximately $8.5 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 8.2% to reach about $14.3 billion by 2028, driven largely by the rising prevalence of diabetes and obesity. The U.S. accounts for roughly 60% of this market, highlighting its dominance domestically.
In the United States, the total addressable market for liraglutide—including its use for both diabetes and obesity—exceeds $6 billion annually. The adoption of newer GLP-1 derivatives and increased utilization in clinical practice push this figure upward.
Competitive Environment
Victoza faces competition from several injectable and oral GLP-1 receptor agonists, including:
- Semaglutide (Ozempic, Rybelsus)
- Dulaglutide (Trulicity)
- Exenatide (Byetta, Bydureon)
Despite competition, Victoza retains a significant market share, attributed to its established clinical efficacy and familiarity among prescribers.
Prescription Trends
Prescription volumes for Victoza peaked around 2019-2020, with a subsequent plateau and minor decline attributable to the launch of semaglutide formulations and shifting prescribing patterns. According to IQVIA data, Liraglutide prescriptions in the U.S. decreased by approximately 5% in 2022 but stabilize due to expanded indications, most notably for obesity management.
Pricing and Reimbursement Dynamics
Current Pricing Landscape
The average wholesale price (AWP) for Victoza stands around $1,200 - $1,350 per pen (each pen contains 3 mL, typically 18 mg of liraglutide). However, net prices after pharmacy discounts and rebates commonly settle around $900 - $1,050 per pen.
payer Coverage and Formularies
Commercial insurance plans and Medicare Part D carriers heavily influence the drug’s net revenue. Victoza is generally favored in formulary tiers due to its efficacy profile, although newer competitors have prompted payers to negotiate tighter discounts.
Reimbursement Trends
Increased utilization in obesity treatment, which often faces less restrictive coverage, has broadened reimbursement pathways, albeit with some payer pushback on off-label use. Medicare coverage has historically been limited for obesity, but recent policy adjustments are expected to influence market dynamics.
Regulatory and Patent Status
Patent protection for Victoza expired in 2023 in the United States, opening avenues for biosimilar competition. Approval of biosimilars with lower prices could exert downward pressure on Victoza’s price points over the next 3-5 years.
The FDA’s biosimilar pathway for liraglutide has seen gradual progress, with at least two biosimilars in development. The entry of biosimilars is projected to reduce the net pricing of Victoza by 15-25% within the next 2-4 years.
Market Drivers and Growth Opportunities
- Expanding indications: Obesity treatment approval in 2022 has opened new revenue streams.
- Clinical acceptance: Growing evidence supports liraglutide’s cardiovascular benefits, bolstering its adoption.
- Innovative formulations: The development of longer-acting formulations and combination therapies will influence pricing and market share.
- Pipeline developments: Ongoing clinical trials for additional indications, including NASH and pediatric populations, have the potential to increase demand.
Price Projections (2023–2028)
Short-term outlook (2023-2025)
- Stability with slight decreases: Currently, Victoza’s net price is expected to decline marginally (~3-5%) due to increased competition and rebate pressures.
- Impact of biosimilars: Introduction of biosimilars in 2024-2025 could lead to a price reduction of approximately 10%, contingent upon market acceptance.
Medium to long-term outlook (2026-2028)
- Gradual decline: Consolidating biosimilar market entry and potential biosimilar price discounts could lead to a 15-20% reduction in net prices.
- Emerging competition: New oral GLP-1 options and fixed-dose combinations might further pressure prices, especially in therapeutically similar segments.
- Market growth offsets: Rising indications and expanded reimbursement for obesity management could offset some pricing erosion through volume growth.
Strategic Implications
Stakeholders should anticipate moderate price erosion but leverage expanding indications and clinical advantages to sustain revenues. Payers' increasing willingness to reimburse for obesity indications may buffer declines. Additionally, companies investing in biosimilar development are poised to redefine the competitive landscape, potentially reducing Medicaid and commercial pharmacy costs.
Key Takeaways
- The global GLP-1 receptor agonist market is robust, with Victoza as a significant player, but faces imminent biosimilar competition.
- U.S. prescription volumes are plateauing but can rebound via expanded obesity indications and clinical benefits.
- Price pressures are anticipated to increase from biosimilars and intensified competition, with estimated net price declines of 10-20% over the next 2-4 years.
- Growth opportunities exist in emerging indications, especially obesity therapy, which may sustain top-line growth despite price erosion.
- Stakeholder strategies should include preparing for biosimilar market entry and capitalizing on expanding indications, data, and new formulations.
FAQs
1. What is the expected impact of biosimilars on Victoza’s price?
Biosimilar entry, projected around 2024-2025, is expected to reduce Victoza’s net price by approximately 10-15%, primarily through increased market competition and rebate negotiations.
2. How does Victoza compare to newer GLP-1 receptor agonists in terms of pricing?
While Victoza currently commands higher net prices, newer agents like semaglutide tend to have higher acquisition costs but may offer formulary advantages and better patient adherence due to once-weekly dosing, influencing overall cost-effectiveness.
3. What are the key growth drivers for Victoza in the next five years?
Expansion of indications—including obesity—and increased clinical acceptance, especially for cardiovascular risk reduction, will drive growth, partly offsetting pricing declines from biosimilars.
4. How does regulatory status influence market projections for NDC 00591-5661?
Patent expiration in 2023 opens the market for biosimilars, creating downward pricing pressure but also opportunities for new formulations and expanded indications to sustain market share.
5. What strategic actions should investors consider?
Investors should monitor biosimilar development pipelines, regulatory approvals, and indications expansion, while also assessing payer reimbursement trends to anticipate pricing and volume shifts.
References
- IQVIA. U.S. Prescription Data.
- Grand View Research. Global GLP-1 Receptor Agonist Market Analysis.
- FDA. Biosimilar Development and Approval Updates.
- MarketWatch. Pharmaceutical Price Trends and Payer Dynamics.
- Centers for Medicare & Medicaid Services. Medicare Coverage & Policy Updates.
More… ↓
